2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-13247
    Setrobuvir
    		Inhibitor
    Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC50s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition.
    Setrobuvir
  • HY-136298
    (Rac)-X77
    		Inhibitor 99.65%
    (Rac)-X77?is a racemate of X77. X77 is a potent non-covalent inhibitor of the main protease of SARS-CoV-2 (SARS-CoV-2 Mpro). X77 binds to SARS-CoV-2 Mpro with a Kd value of 0.057 μM.
    (Rac)-X77
  • HY-132169
    HCoV-229E-IN-1
    		Inhibitor 99.16%
    HCoV-229E-IN-1 is a potent inhibitor of HCoV-229E replication, with an EC50 of 0.65 μM and 0.6 μM in MTS and CPE cells, respectively.
    HCoV-229E-IN-1
  • HY-10241A
    Simeprevir sodium
    		Inhibitor
    Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses.
    Simeprevir sodium
  • HY-W031727S
    Hydroxychloroquine-d4-1 sulfate
    		Inhibitor ≥98.0%
    Hydroxychloroquine-d4-1 (sulfate) is the deuterium labeled Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro[1][2][3].
    Hydroxychloroquine-d<sub>4</sub>-1 sulfate
  • HY-E70127
    Serratiopeptidase
    		Inhibitor
    Serratiopeptidase is an anti-inflammatory agent. Serratiopeptidase has anti-inflammatory, anti-biofilm, mucolytic, fibrinolytic, and wound-healing properties. Serratiopeptidase can be used for combat COVID-19-induced respiratory syndrome research.
    Serratiopeptidase
  • HY-N11902
    1,7-Bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one
    		Inhibitor
    1,7-Bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one is a potent nucleocapsid (N) protein inhibitor can be isolated from Curcuma kwangsiensis. 1,7-Bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one exhibits excellent antiviral activity against HCoV-OC43 and SARS-CoV-2,with EC50 values of 0.16 μM and 0.17 μM, respectively.
    1,7-Bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one
  • HY-138170A
    ALC-0315 (Excipient)
    		99.86%
    ALC-0315 Excipient is an ionisable aminolipid that is responsible for mRNA compaction and aids mRNA cellular delivery and its cytoplasmic release through suspected endosomal destabilization. ALC-0315 Excipient can be used to form lipid nanoparticle (LNP) delivery vehicles. Lipid-Nanoparticles have been used in the research of mRNA COVID-19 vaccine.
    ALC-0315 (Excipient)
  • HY-100304A
    KW-8232
    		Inhibitor 98.10%
    KW-8232, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2.
    KW-8232
  • HY-19727
    FOY 251 free base
    		Inhibitor
    FOY 251 free base, an anti-proteolytic active metabolite of Camostate (HY-13512), acts as a proteinase inhibitor. FOY 25 free base inhibits SARS-CoV-2 infection in cells assay.
    FOY 251 free base
  • HY-132886
    SARS-CoV-2-IN-6
    		Inhibitor 99.94%
    SARS-CoV-2-IN-6 is a SARS-CoV-2 3CLpro inhibitor that shows the most potent enzyme inhibitory IC50 value of 73 nM.
    SARS-CoV-2-IN-6
  • HY-161356
    BPR3P0128
    		Inhibitor 98.58%
    BPR3P0128 is an orally active, non-nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor that has been shown to inhibit the activity of various SARS-CoV-2 variants. The EC50 for SARS-CoV-2 and HCoV-229E are 0.62 μM and 0.14 μM. BPR3P0128 demonstrates effective anti-pancoronavirus activity within the submicromolar range. PR3P0128 shows synergistic antiviral activity when combined with Remdesivir (HY-104077).
    BPR3P0128
  • HY-145592
    Ruzotolimod
    		99.92%
    Ruzotolimod (RO7020531) is an orally active TLR7 agonist. Ruzotolimod inhibits WHV viral replication and, in combination with RO-7049389 (HY-145579), inhibits AAV-HBV viral load. Ruzotolimod can be used to study infection with COVID-19 or SARS-CoV-2.
    Ruzotolimod
  • HY-135867D
    NHC-diphosphate
    		Inhibitor 98.80%
    NHC-diphosphate is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form. NHC is a pyrimidine ribonucleoside and behaves as a potent anti-virus agent. NHC effectively inhibits the replication of venezuelan equine encephalitis virus (VEEV), Chikungunya virus (CHIKV)  and hepatitis C virus (HCV).
    NHC-diphosphate
  • HY-135867
    NHC-triphosphate
    		Inhibitor 99.80%
    NHC-triphosphate is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form. NHC-triphosphate is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA.
    NHC-triphosphate
  • HY-N0191R
    Andrographolide (Standard)
    		Inhibitor
    Andrographolide (Standard) is the analytical standard of Andrographolide. This product is intended for research and analytical applications. Andrographolide is a NF-κB inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.
    Andrographolide (Standard)
  • HY-157778
    MK-7845
    		Inhibitor
    MK-7845 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC50 of 8.7 nM.
    MK-7845
  • HY-144771
    SARS-CoV-2-IN-14
    		Inhibitor 99.02%
    SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.39 μM. SARS-CoV-2-IN-14 is a niclosamide analogue. SARS-CoV-2-IN-14 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally.
    SARS-CoV-2-IN-14
  • HY-153533
    GRL-1720
    		Inhibitor
    GRL-1720 is a potent SARS-CoV-2 Mpro inhibitor with an EC50 value of 15 µM. GRL-1720 shows anti-SARS-CoV2 activity.
    GRL-1720
  • HY-100227
    E 64c
    		Inhibitor 99.73%
    E 64c is a derivative of naturally occurring epoxide inhibitor of cysteine proteases, a Calcium-activated neutral protease (CANP) inhibitor and a very weak irreversible cathepsin C inhibitor. E 64c exhibits entry-blocking effect for MERS-CoV.
    E 64c
Cat. No. Product Name / Synonyms Species Source